The European Investment Bank (EIB), backed by the European Fund for Strategic Investments (EFSI), will provide 25 million euros ($29 million) of financing to Minoryx Therapeutics, a Spanish biotech company specializing in the advancement of treatments for rare central nervous system disorders.
The newly-available funding will thus benefit Minoryx' research and development activities in orphan genetic diseases for which there are currently no approved drugs available.
Just over a month ago, Minoryx signed a deal with China’s Sperogenix Therapeutics exclusive rights to develop and sell leriglitazone, Minoryx' brain penetrating disease-modifying PPAR-γ agonist the therapy, in China, Hong Kong and Macau, for X-linked adrenoleukodystrophy (X-ALD). This deal is worth a potential $78 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze